Specifically, it inhibits N‐Ras depalmitoylation in AML cells and disrupts the balance of N‐Ras palmitoylation, suggesting ABHD17 as a promising target for the treatment of N‐Ras mutant tumors.604. The gene discussed is NRAS; the disease is acute myeloid leukemia.